文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

5'tiRNA-32-LysCTT-11通过稳定Mfn2并抑制线粒体功能障碍介导的坏死性凋亡减轻脓毒症诱导的心肌损伤

5'tiRNA-32-LysCTT-11 ALLEVIATES SEPSIS-INDUCED MYOCARDIAL INJURY BY STABILIZING Mfn2 AND INHIBITING MITOCHONDRIAL DYSFUNCTION-MEDIATED NECROPTOSIS.
PubMed 文献 · Shock · 2026-03-16
一句话结论小鼠与细胞实验显示,5'tiRNA-32-LysCTT-11通过稳定Mfn2 mRNA、保护线粒体、抑制坏死性凋亡减轻脓毒症心肌损伤,作者认为其是有前景的治疗靶点。

本研究在小鼠盲肠结扎穿孔脓毒症模型和脂多糖刺激巨噬细胞条件培养基处理的H9C2心肌细胞中,探讨5'tiRNA-32-LysCTT-11对脓毒症诱导心肌损伤的作用及机制。体内过表达该tsRNA改善心功能并降低损伤生物标志物;体外模拟物保护线粒体完整性、减少活性氧和三磷酸腺苷耗竭、抑制线粒体相关内质网膜形成和坏死性凋亡,抑制剂则产生相反效应。机制上该tsRNA增强Mfn2 mRNA稳定性与蛋白表达,沉默Mfn2消除其保护作用。作者认为5'tiRNA-32-LysCTT-11是脓毒症心肌病有前景的治疗靶点。

要点

  • 在盲肠结扎穿孔小鼠模型中,过表达5'tiRNA-32-LysCTT-11改善心功能并降低心肌损伤生物标志物。
  • 在脂多糖刺激巨噬细胞条件培养基处理的H9C2心肌细胞中,该tsRNA模拟物保护线粒体完整性、减少活性氧和三磷酸腺苷耗竭。
  • 该tsRNA模拟物抑制线粒体相关内质网膜形成和坏死性凋亡,抑制剂转染产生相反效应。
  • 机制上该tsRNA增强Mfn2 mRNA稳定性与蛋白表达,沉默Mfn2可消除其保护作用。
  • 作者认为5'tiRNA-32-LysCTT-11是脓毒症心肌病有前景的治疗靶点。

适用人群与场景

  • 小鼠盲肠结扎穿孔脓毒症模型及脂多糖刺激巨噬细胞条件培养基处理的H9C2心肌细胞。

研究设计与关键结果

  • 研究类型为动物实验与体外细胞实验;小鼠脓毒症模型采用盲肠结扎穿孔建立,心肌损伤通过血清肌酸激酶-MB同工酶/乳酸脱氢酶水平、组织学和超声心动图心功能评估。
  • 在体内,过表达5'tiRNA-32-LysCTT-11改善心功能并降低损伤生物标志物。
  • 在体外,5'tiRNA-32-LysCTT-11模拟物保护线粒体完整性、减少活性氧和三磷酸腺苷耗竭、抑制线粒体相关内质网膜形成和坏死性凋亡;抑制剂转染产生相反效应。
  • 机制上,5'tiRNA-32-LysCTT-11增强Mfn2 mRNA稳定性与蛋白表达;沉默Mfn2消除其保护作用,证实Mfn2在该tsRNA作用中的核心地位。

证据类型、等级与局限

  • 证据类型:动物实验与体外细胞实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为5'tiRNA-32-LysCTT-11是脓毒症心肌病有前景的治疗靶点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Transfer RNA-derived small RNAs (tsRNAs) represent a novel class of noncoding RNAs increasingly implicated in cardiovascular regulation. However, their roles in sepsis-induced cardiomyopathy (SICM) remain largely undefined. This study aimed to investigate the function and underlying mechanism of 5'tiRNA-32-LysCTT-11-a highly upregulated tsRNA in sepsis-induced cardiomyopathy-in modulating myocardial injury.

METHODS: A murine model of sepsis was established via cecal ligation and puncture, and myocardial injury was assessed by serum Creatine Kinase-MB Isoenzyme/lactate dehydrogenase levels, histology, and cardiac function via echocardiography. In vitro , H9C2 cardiomyocytes were exposed to conditioned media from lipopolysaccharide-stimulated macrophages. The expression of 5'tiRNA-32-LysCTT-11 was measured by quantitative reverse transcription polymerase chain reaction. Functional assays, including Cell Counting Kit-8, lactate dehydrogenase release, propidium iodide staining, 5,5',6,6'-Tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine (JC-1), adenosine triphosphate, reactive oxygen species detection, and MitoTracker staining, were performed. Necroptosis was evaluated via mixed lineage kinase domain-like phosphorylation; mitochondria-associated endoplasmic reticulum membranes (MAMs) formation was assessed by dual-label immunofluorescence and phosphofurin acidic cluster sorting protein 2 expression. Bioinformatics analysis identified mitofusin 2 (Mfn2) as a putative target, validated by western blot, mRNA stability assay (actinomycin D), and rescue experiments.

FINDINGS: 5'tiRNA-32-LysCTT-11 was significantly upregulated insepsis-induced cardiomyopathy. In vivo , its overexpression improved cardiac function and reduced injury biomarkers. In vitro , 5'tiRNA-32-LysCTT-11 mimics preserved mitochondrial integrity, reduced reactive oxygen species and adenosine triphosphate depletion, suppressed mitochondria-associated endoplasmic reticulum membranes formation and necroptosis. Inhibitor transfection produced opposite effects. Mechanistically, 5'tiRNA-32-LysCTT-11 enhancedmitofusin 2 mRNA stability and protein expression. Silencing mitofusin 2 abrogated the protective effects, confirming its central role in the tsRNA's action.

INTERPRETATION: 5'tiRNA-32-LysCTT-11 exerts cardioprotective effects during sepsis by stabilizing Mfn2 mRNA, preserving mitochondrial function, limiting mitochondria-associated endoplasmic reticulum membranes formation, and suppressing necroptosis. These findings uncover a novel regulatory mechanism and suggest 5'tiRNA-32-LysCTT-11 as a promising therapeutic target SICM.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Li J, Yuan L, Lin X, et al. 5'tiRNA-32-LysCTT-11 ALLEVIATES SEPSIS-INDUCED MYOCARDIAL INJURY BY STABILIZING Mfn2 AND INHIBITING MITOCHONDRIAL DYSFUNCTION-MEDIATED NECROPTOSIS. Shock. 2026. PMID: 41886619. doi:10.1097/SHK.0000000000002821

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。